New updates have been reported about 4BIO Capital.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
4BIO Capital has expanded its senior investment team by promoting Dr. Therese (Thera) Liechtenstein to Partner and appointing Dr. Tetsuyuki (Tetsu) Maruyama as Venture Partner, moves that deepen its execution capacity in precision therapies and sharpen its geographic reach. Liechtenstein, who joined 4BIO in 2024 and has served as Investment Director, has already led an oversubscribed $75.5 million Series A for Actithera and helped steer Araris Biotech’s sale to Taiho Pharmaceutical in a deal worth up to $1.14 billion, reinforcing 4BIO’s track record in value creation and late‑stage strategic exits.
In her new Partner role, Liechtenstein is expected to play a central part in shaping 4BIO’s portfolio strategy from platform formation through clinical translation, leveraging prior experience at M Ventures where she led seed and Series A investments across Europe and North America. Maruyama, based in Japan and bringing more than 20 years of global neuroscience and translational R&D leadership from Merck, GlaxoSmithKline, Takeda, and the Dementia Discovery Fund, joins as Venture Partner to help 4BIO source and build companies around Japanese innovation, particularly in complex neurological and degenerative diseases. According to Managing Partner Dima Kuzmin, their combined scientific depth and deal experience are intended to strengthen 4BIO’s ability to originate, structure, and scale biotech platforms globally, while positioning the firm to capture emerging opportunities in Japan and in next‑generation precision therapies targeting high unmet medical need.